

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs – A Workshop

January 30, 2024 | 10:00am–5:00pm ET

January 31, 2024 | 10:00am–4:15pm ET

A Virtual Event

ATTENDEE PACKET




Table of Contents

Agenda	3
Biosketches of Speakers, Moderators and Planning Committee	9
Statement of Discrimination, Harassment, and Bullying	22
Diversity, Equity, and Inclusion Statement and Guiding Principles	23

Agenda

Virtual Meeting

TUESDAY, JANUARY 30, 2023

WEDNESDAY, JANUARY 31, 2023

Objectives

- Explore the current state of knowledge and evidence gaps regarding delivering harm reduction services for PWUD in communities, including evidence on best practices for engaging PWUD who are not currently accessing treatment or harm reduction services, as well as inclusive service delivery practices.
- Examine data collection coverage and gaps at the local, state, and federal levels regarding the current state of harm reduction practices in the U.S., including survey research and program and grant evaluations.
- Discuss evidence on barriers to the implementation of harm reduction services and programs at the local, state and federal levels, and the impact of regulatory barriers relative to other factors affecting harm reduction services.
- Explore future data collection needs and key opportunities for federally-sponsored harm reduction research.

DAY 1: TUESDAY, JANUARY 30, 2024

10:00am Welcome and Opening Remarks

Alan Leshner, CEO Emeritus, American Association for the Advancement of Science (AAAS); Former Director, National Institute on Drug Abuse (NIDA); *Workshop Chair*

Session I: Harm Reduction Strategies – A Historical Perspective and an Overview of Where We Are Today

- Review the current state of knowledge regarding the clinical utilization of implantable brain stimulation across various CNS disorders and consider the future potential to improve quality of life for patients.
- Discuss the lessons learned from other technologies that have or have not “crossed the chasm” to become adopted into clinical care.
- Consider how these lessons learned might be applied to implantable brain stimulation.

10:05am Overview

Alan Leshner, CEO Emeritus, AAAS; Former Director, NIDA; *Workshop Chair, Session Co-Moderator*

Keynotes on Harm Reduction Policies and Research Strategies

10:10am Perspectives on the Current and Historical Landscape of Policies on Harm Reduction Strategies

Scott Burris, Temple University

Daliah Heller, Vital Strategies

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs: A Workshop

10:30am Overview of the Evidence base for Harm Reduction Strategies

Nabarun Dasgupta, University of North Carolina; *Planning Committee Member*

10:50am Moderated Discussion with Speakers and Q&A

Opening Talks Highlighting Lived Experience

11:05am Overview

Stephen Murray, Boston Medical Center; *Planning Committee Member; Session Co-Moderator*

11:10am Panelists

Steve Alsum, The Grand Rapids Red Project

David Frank, New York University

Mark Jenkins, Connecticut Harm Reduction Alliance

Dinah Ortiz, National Survivors Union

Caty Simon, Whose Corner Is It Anyway

11:50am Moderated Discussion with Speakers

12:10pm ONDCP Presentation – Goals and Priorities of the Administration

Rahul Gupta, Director, Office of National Drug Control Policy, Executive Office of the President

12:20pm BREAK

Session II: Evidence from Harm Reduction Programming Outside the United States

- Provide an overview of the evidence base for harm reduction internationally.
- Examine best practices and lessons learned from research abroad.

12:30pm Session Overview

Magdalena Cerdá, New York University; *Planning Committee Member; Session Moderator*

12:35pm Research Perspectives from Abroad

Marie Jauffret-Roustide, Institut National de la Santé et de la Recherche Médicale

Thomas Kerr, University of British Columbia

Jaime Arredondo, University of Victoria

1:05pm Moderated Discussion with Speakers and Q&A

1:25pm LUNCH

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs: A Workshop

Session III: Federal Landscape for Harm Reduction Research

- Examine the current state of data collection coverage and gaps at the federal level including survey research and program and grant evaluations.
- Discuss evidence on barriers to the implementation of harm reduction services at the federal level.

2:00pm Session Overview

Chinazo Cunningham, New York State Office of Addiction Services and Supports;
Planning Committee Member; Session Moderator

2:05pm National Institute on Drug Abuse (NIDA)

Nora Volkow, Director

2:15pm Substance Abuse and Mental Health Services Administration (SAMHSA)

Yngvild Olsen, Director for the Center for Substance Abuse Treatment

2:25pm Centers for Disease Control and Prevention (CDC)

Grant Baldwin, Director of the Division of Overdose Prevention

2:35pm Indian Health Service (IHS)

David Paschane, National Data Coordinator for the Office of Clinical and Preventative Services

2:45pm Drug Enforcement Administration (DEA)

Gamaliel Rose, Section Chief of Statistical Services

2:55pm Moderated Discussion with Speakers and Q&A

3:15pm BREAK

Session IV: Strategies for Harm Reduction Research, Implementation, and Data Collection at the Local and State Level

- Examine the current state of data collection coverage and gaps at the local and state levels.
- Discuss evidence on barriers to the implementation of harm reduction services at the local and state levels.
- Discuss evidence needs to guide implementation strategies.
- Explore the tension between data demands and ability to provide harm reduction services to PWUD.
- Discuss the effects that laws can have at state/local levels as barriers or facilitators.
- Discuss whether harm reduction data ought to be shared across programs, and if so, how.

3:25pm Session Overview

Jeffrey Hom, San Francisco Department of Public Health; *Planning Committee Member; Session Moderator*

3:30pm Evaluating Harm Reduction Programming Across Localities

Brandon Marshall, Brown University

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs: A Workshop

3:45pm Data Needs, Evidence Gaps, and Successes from State and Local Programs

Hillary Kunins, San Francisco Department of Public Health

Erin Russell, Health Management Associates

Elizabeth Salisbury-Afshar, Wisconsin Department of Health Services –

Joshua Swatek, New Mexico Department of Health

A. Toni Young, Community Education Group

4:35pm Moderated Discussion with Speakers and Q&A

4:55pm Day 1 Closing Remarks

Alan Leshner, CEO Emeritus, AAAS; Former Director, NIDA; Workshop Chair

5:00pm ADJOURN

DAY 2: WEDNESDAY, JANUARY 31, 2024

10:00am Welcome and Recap of Day 1

Alan Leshner, CEO Emeritus, AAAS; Former Director, NIDA; *Workshop Chair*

Session V: Special Considerations for Research and Data Collection with Underserved Populations

- Highlight best practices for engaging PWUD who are not accessing harm reduction services or treatment.
- Examine the role of stigmatization and why certain populations may not be accessing harm reduction services.
- Discuss evidence on barriers to the implementation of harm reduction services for underserved populations.

10:10am Session Overview

Tracie Gardner, Legal Action Center; Planning Committee Member; Session Moderator

10:15am Addressing Racial Inequities in the Effectiveness of Harm Reduction Services

Ricky Bluthenthal, University of Southern California

Considerations for Special Populations and Circumstances

10:35am Pregnant and Parenting People

Tracy Nichols, Lehigh University

10:45am Gender-Expansive People

Kiku Johnson and Haven Wheelock, Outside In

10:55am Individuals Experiencing Homelessness

Margot Kushel, University of California – San Francisco

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs: A Workshop

11:05am Indigenous Communities

Sharon Day, Indigenous Peoples Task Force

11:15am Moderated Discussion with Speakers and Q&A

11:45pm BREAK

Session VI: Envisioning a National Research Agenda for Harm Reduction

- Consider innovations and best practices (e.g., provider education/training), including those from the COVID-19 pandemic, that could be more broadly implemented within the existing regulatory framework to support access to harm reduction services.
- Discuss data needs to inform the implementation of harm reduction services, including making them adaptable to the ever-changing landscape of the illicit drug market.
- Explore methodologies as well as infrastructure, funding, and data needs for scaling harm reduction strategies.
- Explore future data collection needs and key opportunities for federally-sponsored harm reduction research.
- Invite individuals to highlight and prioritize key research needs moving forward.

11:55am Session Overview

Alan Leshner, CEO Emeritus, AAAS; Former Director, NIDA; *Workshop Chair; Session Moderator*

12:00pm Approaches for Optimizing Research and Implementation of Harm Reduction Services

Sarah Brothers, Pennsylvania State University

Ju Park, Brown University

Alexander Walley, Boston University

12:30pm Moderated Discussion with Speakers and Q&A

1:00pm LUNCH

1:35pm Considerations for Scaling Harm Reduction Research and Implementation and Sharing Data, When Appropriate

Peter Davidson, University of California – San Diego

Emmanuel Oga, RTI International

Hansel Tookes, University of Miami

2:05pm Moderated Discussion with Speakers and Q&A

2:35pm BREAK

2:45pm Synthesis of Research Needs

Nabarun Dasgupta, University of North Carolina; Planning Committee Member

Harm Reduction Services for People Who Use Drugs: Exploring Data Collection, Evidence Gaps, and Research Needs: A Workshop

3:00pm Reflections on Concrete Next Steps

Ricky Bluthenthal, University of Southern California

Magdalena Cerdá, New York University; *Planning Committee Member*

Corey Davis, Network for Public Health Law; *Planning Committee Member*

Ruchi Fitzgerald, Rush University; *Planning Committee Member*

Tracie Gardner, Legal Action Center; *Planning Committee Member*

Raagini Jawa, University of Pittsburgh

3:30pm Moderated Discussion with Speakers and Q&A

4:10pm Acknowledgements and Concluding Remarks

Alan Leshner, CEO Emeritus, AAAS; Former Director, NIDA; *Workshop Chair*

4:15pm ADJOURN

This event is sponsored by the Office of National Drug Control Policy, Executive Office of the President and was planned by the following experts: Alan Leshner (*Chair*), CEO Emeritus, American Association for the Advancement of Science, Forum Director, National Institute on Drug Abuse; Magdalena Cerdá, New York University; Chinazo Cunningham, New York State Office of Addiction Services and Supports; Chin Hwa (Gina) Dahlem, University of Michigan; Nabarun Dasgupta, University of North Carolina; Corey Davis, Network for Public Health Law; Ruchi Fitzgerald, Rush University; Tracie Gardner, Legal Action Center; Helena Hansen, University of California – Los Angeles; Jeffrey Hom, San Francisco Department of Public Health; Kevin Larsen, Optum; Stephen Murray, Boston Medical Center; and Glyceria (Ria) Tsinas, Academy of Perinatal Harm Reduction.

Note: The planning committee's role is limited to organizing the event. A proceedings based on the event will be prepared by independent rapporteurs.

Article I. Biosketches of Speakers



Scott Burris, JD

Scott Burris is a Professor of Law and Public Health at Temple University, where he directs the Center for Public Health Law Research. His work focuses on how law influences public health, and what interventions can make laws and law enforcement practices healthier in their effects. He is the author of over 200 books, book chapters, articles and reports on issues including urban health, HIV/AIDS, research ethics, and the health effects of criminal law. He founded and directed the Public Health Law Research and Policies for Action programs for the Robert Wood Johnson Foundation, and his work has been supported by organizations including the Open Society Institute, the National Institutes of Health, the Bill and Melinda Gates Foundation, the UK Department for International Development, and the CDC. He has served as a consultant to numerous U.S. and international organizations including WHO, UNODC and UNDP. He has been a visiting scholar at RegNet at the Australian National University, the Center for Health Law at the University of Neuchatel, the Department of Transboundary Legal Studies at the Royal University of Groningen, and the University of Amsterdam. He was a Fulbright Fellow at the University of Cape Town Law School. He has been the recipient of the American Public Health Law Association Health Law Section Lifetime Achievement Award and the Jay Healey Health Law Teachers Award from the American Society of Law, Medicine and Ethics. He is a Fellow of the College of Physicians of Philadelphia and the U.K. Faculty of Public Health (honorary). Professor Burris is a graduate of Washington University in St. Louis (A.B.) and Yale Law School (J.D.). Burris is the premier methodologist in the emerging field of legal epidemiology. He is the co-editor of *Legal Epidemiology: Theory and Methods* (Wiley 2023). The second edition of his public health law text book, *THE NEW PUBLIC HEALTH LAW: A TRANSDISCIPLINARY APPROACH TO PRACTICE AND ADVOCACY*, has just been published by Oxford University Press, and a global edition is in progress.



Daliah Heller, PhD

Daliah Heller is a public health leader who has worked for almost three decades in drug policy and practice to mount a humane health-based response. As Vice President of Drug Use Initiatives at Vital Strategies, she leads a multi-state initiative to reduce overdose deaths in the United States, partnering with state and local governments and supporting communities and providers to catalyze and scale a harm reduction approach. Previously, Daliah was Assistant Commissioner at the New York City Health Department, and before that, Executive Director of a large harm reduction program in the Bronx. For the past decade, she has consulted on drug policies with governments, community leaders, and organizations around the world. She holds a PhD in Social Welfare from City University of New York and MPH from Columbia University and teaches as an Adjunct Lecturer at New York University School of Global Public Health.



Steve Alsum, BS

Steve Alsum has been with the Grand Rapids Red Project in varying capacities, including volunteer, board member, and Clean Works Program Manager, since 2007, and currently serves in the role of Executive Director. The Grand Rapids Red Project is rooted in harm reduction and provides a variety of services in West Michigan, including syringe access, overdose education and naloxone distribution, drug checking, facilitation of the Michigan User Union, mobile health units, access to medications for opioid use disorder, recovery coaching, HIV and hepatitis C testing and linkage to care, HIV case management, and technical assistance. Steve believes it is a basic human right to have access to the knowledge, tools, information, and support needed to maintain health and life, and tries to make these things attainable through his work at The Red Project, specifically as applied to substance use and other stigmatized health issues, like HIV, hepatitis C and overdose. Steve believes the intersection between drug policy and public health is critical to understanding harm that happens in our communities surrounding substance use, and that policy change is essential to community members being able to preserve their health and life. Steve has a BS in Mathematics from Grand Valley State University.



David Frank, PhD

David Frank is a medical sociologist and assistant research scientist at the New York University School of Global Public Health. He is also a person who uses drugs and who has been on methadone maintenance treatment (MMT) for approximately twenty years. His work focuses primarily on MMT and problematizes the use of addiction-and-recovery narratives to conceptualize treatment by demonstrating that many use and benefit from MMT for more pragmatic reasons, such as avoiding or moderating harms and difficulties of active drug use. Dr. Frank is also an activist with the North Carolina Survivors Union and works to help end the War on Drugs policies and practices that have harmed people who use drugs for so many years. He is the current chair of the Society for the Study of Social Problems Drinking & Drugs division and recent recipient of the American Sociological Association Junior Scholar Award (Drinking and Drugs division) for his use of situated methodologies in research with people who use drugs.



Mark Jenkins

Mark Jenkins is a service-connected disabled Veteran of the United States Air Force and Founder / CEO of the Connecticut Harm Reduction Alliance (CTHRA) and Reduce Harm Inc. (RHI). He has worked in the field of harm reduction and public health for the past twenty-seven years, delivering innovative prevention/interventions to the most vulnerable members of central Connecticut communities. Mr. Jenkins started in the field as an AIDS Risk Reduction Outreach Worker (ARROW) for the Perception programs in Willimantic. In his subsequent work with Community Renewal Team (CRT) and the Hispanic Health Council he further cultivated progressive strategies for reaching and delivering services to our most difficult-to-reach populations. Mr. Jenkins has worked in some of the most troubled neighborhoods in the state which has given him a unique perspective of the history of drug trends, the dynamics of associated risks, and effective public health responses. He has worked over a decade on the staff at AIDS Project Hartford as a Drug Treatment Advocate providing HIV/HCV counseling and testing, syringe exchange, and other harm reduction services. Mr. Jenkins developed a service network of providers that continues to benefit both client and staff of the various providers alike. The breadth and depth of his connection with folks on the street and the service community has made Mr. Jenkins a well-respected and widely known individual in this field. He has presented nationally and internationally about best practices for working with the drug using community.



Dinah Ortiz

Dinah Ortiz is a Drug User Human Rights Activist whose expertise focuses on working predominantly with marginalized pregnant and parenting people who use drugs. As an independent consultant and coming out of direct parent representation for over a decade, she had an impactful realization that there was something missing in the representation of marginalized parents who use drugs, educating the misinformed that parents do not have to remain abstinent to effectively parent their children despite what the courts, public policy, and the many structural systems of oppression dictate. Dinah has appeared on hundreds of panels nationwide to discuss harm reduction strategies among other drug user topics, highlighting the unique challenges facing parents affected by the family policing system who happen to use illicit substances. Her primary goal is to disrupt the narratives of all oppressive systems.



Caty Simon

Caty Simon has spent more than 20 years in the low-income rights, psychiatric survivors' rights, sex workers' rights, and drug users' union movements. She is a Leadership Team Member of National Survivors Union (NSU), the United States national drug user's union. Simon is also a founding co-organizer and Development Director of Whose Corner Is It Anyway, a Western MA harm reduction, mutual aid, and organizing group by and for low-income, street, and survival sex workers who use opioids and/or stimulants and/or experience housing insecurity. She is the Narrative Development Director at NC Survivors Union, the flagship affiliate group of NSU, leading Narco-feminism Story share, a project reducing stigma and disrupting stereotypes against people who use drugs through collaborative autobiographical story development and stakeholder training. From 2013 to 2020, Simon was co-editor of Tits and Sass (titsandsass.com), a seminal media outlet by and for sex workers which was featured in the New Yorker, the New York Times, Jezebel, Gawker, and the New Inquiry, to name a few. She is first author of a commentary in the International Journal of Drug Policy on union members' experiences as drug user organizers doing community driven research (CDR) and an editorial in a health justice and overdose crisis supplemental issue of the American Journal of Public Health.



Rahul Gupta, MD, MPH, MBA, FACP

Rahul Gupta is the first medical doctor to serve as the Director of National Drug Control Policy and lead the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President. ONDCP coordinates the nation's \$43 billion drug budget and federal policies, including prevention, harm reduction, treatment, recovery support, and supply reduction. Through his work as a physician, a state and local leader, an educator, and a senior leader of a national nonprofit organization, Dr. Gupta has dedicated his career to improving public health and public safety. A board-certified internist, Dr. Gupta has been a practicing primary care physician for more than 25 years and has served in private practice and public health in towns as small as 1,900 residents and cities as large as 25 million. He has served as a local public health official and as the West Virginia Health Commissioner under two governors, where he brought together public health, law enforcement, healthcare, faith-based, business, and other community partners to solve local problems in novel and innovative ways. As the state's Chief Health Officer, he led the opioid crisis response and launched a number of pioneering public health initiatives, including the Neonatal Abstinence Syndrome Birthscore program to identify high-risk infants, and the groundbreaking statewide Social Autopsy, which examined the lives of overdose victims to determine the factors that led to their deaths and what services could have prevented their deaths. This led the state to expand access to naloxone as well as treatment services including those for incarcerated individuals in order to save lives and help people transition back into society. He supported the expansion of harm reduction programs to more than a dozen sites across the state. He was also instrumental in expanding state-of-the-art, comprehensive and integrative medical and behavioral health programs for pregnant and postpartum women.



Marie Jauffret-Roustide, PhD

Marie Jauffret-Roustide is a Sociologist, Senior Research Fellow at the French National Institute of Health and Medical Research in Paris, France. She leads an international comparative research project on drug policies that focuses on the history of harm reduction including the opioids regulations in several settings, the impact of prohibitive regimes on people who use drugs' trajectories, and the evaluation processes and controversies on drug consumption rooms. She is the scientific director of the D3S Social Science, Drugs and Society Program at the Advanced School of Social Science.



Thomas Kerr, PhD

Thomas Kerr is the Director of Research with the BC Centre on Substance Use (BCCSU) and is a professor and the Head of the Division of Social Medicine in the Department of Medicine at the University of British Columbia. Dr. Kerr holds a doctoral degree in health psychology and brings over 15 years of clinical experience working with a range of populations, including people who use substances, individuals living with mental illnesses, and people living with HIV. His primary research interests involve substance use, harm reduction, HIV/AIDS, and health policy and service evaluation. His long history of involvement in healthcare issues in Vancouver's Downtown Eastside includes ground-breaking work on peer-driven interventions, needle exchanges, and supervised consumption sites. Dr. Kerr has also worked in a number of settings internationally, including in Thailand, Argentina, Australia, France, the US, Russia, Eastern Europe, and the former Soviet Union. Dr. Kerr's work impacts policy and practice both close to home and internationally. At home in Vancouver, his leadership in research on needle exchanges and supervised consumption sites has helped inform the redesign of harm reduction programs locally and internationally. Abroad, his community-based research in Thailand has been cited extensively in reports by the World Bank and the Global Commission on Narcotic Drugs. Dr. Kerr has provided invited expert testimony to House of Commons and Senate committees, the United Nations, and he was an expert witness for the Missing Women's Commission of Inquiry. Dr. Kerr has published more than 700 scientific papers in international peer-reviewed journals and has received numerous local and national awards for his contributions to public health, human rights, and the fight against HIV/AIDS. He has received the Providence Health Care, Department of Medicine, and UBC Martin M. Hoffman Award for Excellence in Research. He has also been the recipient of the Queen Elizabeth II Diamond Jubilee Medal from the Governor General of Canada, the National Knowledge Translation Award from the Canadian Institutes of Health Research (CIHR) for his efforts to promote scientific discussion on the topic of illicit drug policy.



Jaime Arredondo, PhD

Jaime Arredondo Sanchez Lira is an assistant professor at the School of Public Health and Social Policy (PHSP) at the University of Victoria, B.C. and a Canada Research Chair on Substance Use and Health Policy, at the Canadian Institute for Substance Use Research (CISUR). He completed his Ph.D. in Global Public Health at the University of California, San Diego (UCSD) and San Diego State University (SDSU). In 2013 he helped implement an occupational health and harm reduction police training in the city of Tijuana (ESCUDO). He completed a postdoctoral fellowship at the British Columbia Centre on Substance Use (BCCSU) in Vancouver, Canada, on the implementation and evaluation of a drug testing pilot to address the fentanyl overdose crisis. His work on the US-Mexico border seeks to implement and evaluate evidence-based harm reduction policies such as safe consumption sites, fentanyl drug checking, and community distribution of naloxone to prevent overdoses. His research seeks to transform the public debate by viewing substance use as a public health issue rather than a public safety one.



Nora D. Volkow, MD

Nora D. Volkow is Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health. NIDA is the world's largest funder of research on the health aspects of drug use and addiction. Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a brain disorder. As a research psychiatrist, Dr. Volkow pioneered the use of brain imaging to investigate how substance use affects brain functions. In particular, her studies have documented that changes in the dopamine system affect the functions of frontal brain regions involved with reward and self-control in addiction. She has also made important contributions to the neurobiology of obesity, ADHD, and aging.



Yngvild Olsen, MD, MPH

Yngvild Olsen is the Director for the Center for Substance Abuse Treatment (CSAT) at the Substance Abuse and Mental Health Services Administration (SAMHSA). She has a long history of working within the addiction treatment field to expand access to care and enhance quality and has written and lectured extensively on opioid use disorder and its treatments, the stigma of addiction, the integration of behavioral health and medical care, and clinical and policy solutions to the overdose epidemic. She was previously vice president of the American Society of Addiction Medicine, president of the Maryland Association for the Treatment of Opioid Dependence, and president of the Maryland/DC Society of Addiction Medicine.



Grant Baldwin, PhD, MPH

Grant Baldwin is the Director of the Division of Overdose Prevention at CDC's National Center for Injury Prevention and Control. He leads the division in monitoring trends in the drug overdose epidemic and other emerging drug threats, identifying and scaling up prevention activities to address the evolving drug crisis, and supporting local drug-free community coalitions. Prior to this appointment in October 2019, Dr. Baldwin served as the Director of the Division of Unintentional Injury Prevention for 11 years, where he helped raise the profile of motor vehicle injury prevention, advanced work in older adult fall prevention and traumatic brain injury prevention and established the initial CDC response to the prescription opioid overdose epidemic. As the scope, scale, and complexity of America's drug overdose epidemic changed, the Division of Overdose Prevention was created to serve as a necessary and essential focal point to CDC's more expansive and diversified work in the area. Dr. Baldwin has served at CDC for over 26 years. Dr. Baldwin received his PhD in Health Behavior and Health Education at the University of Michigan. He received an MPH in Behavioral Sciences and Health Education from Emory University and is currently adjunct faculty at Emory University. Dr. Baldwin has given keynote addresses and provided remarks at over 150 state, national, and international conferences, and meetings; has authored or coauthored more than 80 peer-reviewed publications; and has received awards of excellence for his leadership and teaching.



David Paschane, PhD

David Paschane is a health policy and system researcher serving in the role of national data coordinator for the behavioral health mission of the Office of Clinical and Preventive Services for the Indian Health Service. He is a member of Choctaw Nation of Oklahoma, and a military veteran. Dr. Paschane leads analyses of IHS programs and policies, with an emphasis on the local continuums of services for risk mitigation, especially through Tribal governments. With over 30 years of experience among several of the federal agencies, he has addressed many of the relevant human risk and health service issues, at various scales, and among diverse forms of health systems. His research and projects have earned him several notable recognitions, including the HHS Award of Excellence, Federal Leadership 50 Award, and the Computerworld Premier 100 IT Leader Award.



Gamaliel Rose, MS

Gamaliel Rose assumed responsibility for the Statistical Services Section at the Drug Enforcement Administration (DEA), where he has emphasized three priorities: improving data quality and data sharing; improving data utilization by working with internal clients to understand and address analytic opportunities; and fostering steady improvements in DEA data literacy by keeping DEA management informed regarding technical literature, consulting with DEA decision makers to inform policy development, and helping DEA management refine methods/techniques for process improvement. Before joining the DEA in 1999, Mr. Rose devoted ten years to private and public sector management consulting, with an emphasis on using complex data sets to develop and implement best practices in large organizations. Mr. Rose's clients have included approximately 100 major service entities (primarily in the banking and health care industries) and the Department of Defense. Mr. Rose has an undergraduate degree from Yale University (1986) and a master's degree in management from the University of Virginia (1990).



Brandon Marshall, PhD

Brandon Marshall is a professor and vice chair of the Department of Epidemiology at the Brown University School of Public Health. He is also founding director of the People, Place & Health Collective at Brown University. Dr. Marshall's research focuses on substance use epidemiology, with a specific emphasis on harm reduction and overdose prevention. He is passionate about conducting research that improves the health and well-being of people who use drugs.



Hillary Kunins, MD

Hillary Kunins joined the San Francisco Department of Public Health (SFPDH) in March 2021, as the Director of Behavioral Health Services and Mental Health SF. Dr. Kunins joined SFPDH from New York City where she served as the Executive Deputy Commissioner of Mental Hygiene (2019-2021) and Assistant Commissioner for the Bureau of Alcohol and Drug Use (2012-2019) at the New York City Department of Health and Mental Hygiene (DOHMH). At DOHMH, Dr. Kunins led the reimagining of New York City's public health approach to substance use, including overdose as served as the DOHMH lead for Mayor Bill de Blasio's \$60 million Healing NYC initiative to address the overdose epidemic. As a general internist and addiction medicine physician, Dr. Kunins has dedicated her career to health equity for people with behavioral health concerns, including substance use and serious mental illness, through science-based public health and healthcare programs and policy. Dr. Kunins received her MD and MPH from Columbia University and her MS in Clinical Research from Einstein College of Medicine and completed her primary care-internal medicine residency and chief residency at Montefiore/Einstein. Dr. Kunins is a Fellow of American College of Physicians and Fellow of American Society of Addiction Medicine.



Erin Russell, MPH

Erin Russell is a Principal Consultant with Health Management Associates, where she leads a portfolio of projects that expand the reach and acceptability of harm reduction services. She has been immersed in harm reduction for over a decade, building her expertise through experience in advocacy, government, and nonprofit organizations. Prior to joining HMA, she served as the first Chief of the Center for Harm Reduction Services at the Maryland Department of Health. She led statewide naloxone distribution, syringe service programs, a harm reduction grant program, and local capacity-building initiatives. She has been at the forefront of integrating harm reduction into larger behavioral health, opioid response, and infectious disease prevention programming, serving to improve state government capacity to meet the needs of people who use drugs. The mission of Health Management Associates, the largest healthcare-only consulting firm in the United States, is to improve the health and well-being of individuals and communities by making publicly funded healthcare, and the social services that support it, more accessible, equitable, and effective. Comprising over 900 consultants and growing, HMA is a group of trusted advisors offering insights and technical assistance, gained from real-world experience and ongoing work, on the cutting edge of healthcare and social service reform and improvement.



Elizabeth Salisbury-Afshar, MD, MPH

Elizabeth Salisbury-Afshar is an Associate Professor in the Departments of Family Medicine and Community Health and Population Health Sciences at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin. Dr. Salisbury-Afshar is board certified in addiction medicine, preventive medicine/public health, and family medicine, and her expertise lies at the intersection of these fields. Her work has focused on expanding access to evidence-based substance use disorder treatment and harm reduction services. She is currently the Program Director of the Preventive Medicine Residency and core faculty for the Addiction Medicine Fellowship at UW-Madison. She is also the Medical Director of Harm Reduction Services for the Wisconsin Department of Public Health. Past public health roles include serving as Medical Director of Behavioral Health Systems Baltimore, Medical Director of Behavioral Health at the Chicago Department of Public Health, and Director of the Center for Addiction Research and Effective Solutions at the American Institutes for Research. In each of these roles she developed strategy and led program implementation efforts related to the overdose crisis with a focus on substance use disorder treatment and harm reduction service expansion.




Joshua Swatek, BS

Josh graduated from New Mexico State University and has spent his career working in the harm reduction field including working as a community-based outreach worker, New Mexico's first ever overdose prevention coordinator, the viral hepatitis prevention coordinator, and the HIV/HCV planning coordinator. Currently Josh works as the Hepatitis and Harm Reduction Program Manager where he oversees the statewide harm reduction program, viral hepatitis prevention programs, overdose and naloxone distribution services, and the Governor's Office efforts on mobile service delivery to unhoused individuals.



A. Toni Young

A. Toni Young has been the executive director of Community Education Group for 30 years. She focuses on community mobilization, organization management, and collaborative partnerships for marginalized populations. She is extensively involved in HIV/AIDS advocacy and research, leading numerous studies and initiatives. In 2007, she led a study on HIV vulnerability in Black women with partners with incarceration history, crucial for targeted interventions. She has addressed structural HIV prevention factors in African American women with Exchange Coalition, advocating comprehensive approaches and aligning efforts with the strategy for evidence-based interventions grounded in best practices. Her current focus, and the mission of CEG, is to combat the syndemic of HIV, viral hepatitis, and substance use disorder, in Appalachia and rural America.



Ricky Bluthenthal, PhD

Ricky N. Bluthenthal is a Professor in the Department of Populations and Public Health Sciences (DPPHS), Vice Chair for Diversity, Equity and Inclusion in DPPHS, and Associate Dean for Social Justice in the Keck School of Medicine at the University of Southern California. Since 1991, Dr. Bluthenthal has conducted community-partnered research on risk behaviors and health promotion among people who inject drugs (PWID), men who have sex with men, and other disadvantaged populations. His current studies include an observational cohort study on the substitution of cannabis for opioids among PWID, an evaluation of the Hollywood LEAD program, and qualitative, life histories of opioid use among substance using men who have sex with men. His studies have been funded by NIDA, NIAAA, NIMHD, and the CDC among others. Dr. Bluthenthal has published over 190 manuscripts in peer-reviewed scientific journals and is on editorial board of the International Journal of Drug Policy, Drug and Alcohol Dependence, and PLOS ONE. He has received numerous awards including the John P. McGovern Award for Excellence in Medical Education from the Association for Multidisciplinary Education & Research in Substance Use & Addiction, the William Foote Whyte Distinguished Career Award from the Sociological Practice & Public Sociology section of the American Sociological Association, and the Social Science Distinguished Alumni Award.



Tracy Nichols, PhD

Tracy R. Nichols, a Professor of Community and Population Health in the College of Health at Lehigh University, is a behavioral scientist whose expertise includes sexual and reproductive health, substance use, adolescent health, and family health with a core focus on developing and evaluating interventions that reduce health inequities. Dr. Nichols received her bachelor's degree from the New School for Research and her doctorate in developmental psychology from Columbia University. She has applied her knowledge of the social and developmental factors of human behavior to public health issues throughout her career. Her early work at Weill Cornell Medical College, focused on the prevention and etiology of adolescent substance use and violence. She was a member of the team that developed and evaluated the Life Skills Training program, one of the top research-based prevention programs in the US. Her current research agenda aims to improve care services for pregnant and parenting people who use drugs through multi-level stigma reduction interventions. Her research has demonstrated how intersectional stigma serves as a barrier to care engagement as well as how current stigma reduction practices fail to address the organizational and structural elements critical for supporting compassionate care. As a member of the leadership team for Narcofeminism Storyshare, she collaborates with NC Survivors Union, to adapt and evaluate their autobiographical story share process into a stigma reduction training for healthcare and social service providers and to develop and promote their Reproductive Harm Reduction framework.



Kiku Johnson, BA

Kiku Johnson is the Executive Director of Outside In – Portland, a nonprofit organization supporting youth experiencing homelessness and other marginalized people as they move toward improved health and self-sufficiency. He is an intersectional, queer, Chinese, transgender man originally hailing from Michigan. Kiku is an educator, trainer, and consultant engaging his human-centered design thinking, with a visual arts background focused on diversity, equity, and expansion. Kiku has 30+ years of experience with youth development and responsive community program design, outreach, implementation, evaluation, and advocacy through a social justice lens. He is adept at creating culturally, trauma-informed and healing-centered, accessible, affirming approaches and content for a wide variety of intersectional communities including LGBTQIA+, People of Color, immigrants, low-access and low-resourced people, youth, and adults working across sectors including juvenile justice, education, mental health, community-based, and faith-based organizations. Kiku has traveled the country educating on Sexual Orientation, Gender Identity and Expression (SOGIE) Affirming Approach and Expansive Practices. He is a Georgetown University McCourt School of Public Policy/Center for Juvenile Justice Reform, Supporting LGBTQ Youth Program Fellow.



Haven Wheelock, MPH

Haven Wheelock has been advocating for the health and safety of people who use drugs since 2002. Currently, she is the Drug Users Health Services Program Coordinator at Outside In, in Portland Oregon. She provides direct service with people who use drugs and has also been involved in creating policy that improves the health in Oregon. She completed a MPH as a Fellow at Johns Hopkins as part of the Bloomberg American Health Initiative focusing on Overdose and Addiction Policy. She was also a Chief Petitioner for ballot measure 110, which was a first in the nation initiative to decriminalize drugs in the state of Oregon. Haven Wheelock has been advocating for the health and safety of people who use drugs since 2002. Currently she is the Drug Users Health Services Program Coordinator at Outside In in Portland Oregon. She provides direct service with people who use drugs and has also been involved in creating policy that improves the health in Oregon. She completed a MPH as a Fellow at Johns Hopkins as part of the Bloomberg American Health Initiative focusing on Overdose and Addiction Policy. She was also a Chief Petitioner for ballot measure 110, which was a first in the nation initiative to decriminalize drugs in the state of Oregon.



Margot Kushel, MD

Margot Kushel is a Professor of Medicine at University of California San Francisco, and Division Chief and Director of the UCSF Center for Vulnerable Populations, and Director of the UCSF Benioff Homelessness and Housing Initiative. She is a practicing general internist at Zuckerberg San Francisco General Hospital. Dr. Kushel's research focuses on the causes and consequences of homelessness, with the goal of preventing and ending homelessness and ameliorating the effects of homelessness on health. She is the Principal Investigator of the California State Study of People Experiencing Homelessness (CASPEH). She is the Principal Investigator of multiple NIH studies, including the HOPE HOME Study, a longitudinal cohort study of homelessness in older adults Homelessness and a study of advance care planning in permanent supportive housing. She is the Principal Investigator of the California Statewide Study of People Experiencing. Dr. Kushel serves on the board of Housing California and the National Homelessness Law Center and the Steinberg Center. She is a member of the Advisory Board of the California Interagency Council on Homelessness. She speaks at a local, state, and national level about issues of homelessness, and frequently provides testimony to legislative bodies. She received her AB from Harvard College, her MD from Yale and completed residency, chief residency, and fellowship in internal medicine at UCSF.



Sharon Day

Sharon M. Day is the Executive Director of the Indigenous Peoples Task Force located in Minneapolis, Mn. She is the founder of the organization which began as the Minnesota American Indian AIDs Task Force in 19987 and has been the E.D. since 1990. The organization is based in the values and teachings of the anishinabe peoples. IPTF hosts a variety of programming for Indigenous peoples focused on public health including harm reduction, HIV services, housing, youth prevention using theater as the strategy, and includes Indigi Baby Food. Indigi Baby food is based on a pre-colonial Indigenous diet free from sugars, fat, and wheat.



Sarah Brothers, PhD

Sarah Brothers is an assistant professor of Sociology and Public Policy at Pennsylvania State University. She uses qualitative methods including in-depth interviews, ethnographic observations, surveys, Community Engaged Research (CER) and Community Driven Research (CDR) to examine how vulnerable groups experience and respond to health-related issues. Her research areas include methadone treatment, issues facing youth experiencing homelessness, food insecurity, patient perspectives on HIV and hepatitis C (HCV) treatment, overdose responses, injection drug use practices, and ethical implications of CER approaches. Her work has won multiple awards and been supported by the National Science Foundation, the Mellon/ACLS Foundation, and others. She holds a Ph.D. in sociology from Yale University and a B.A in sociology from the University of California Berkeley.



Ju Nyeong Park, PhD, MHS

Ju Nyeong Park is an Assistant Professor of Medicine and Epidemiology at Brown University and a Research Scientist at Rhode Island Hospital. Dr. Park's team, the Harm Reduction Innovation Lab (HRIL) implements and evaluates innovative interventions to promote the health and wellbeing of people who use drugs. Currently, Dr. Park leads and collaborates on several NIH-funded studies including research on: (1) overdose detection technologies (P20GM125507); (2) community-based drug checking (UG3DA056881), and (3) sleep among patients with opioid use disorder (R01DA059469). Dr. Park has extensive experience conducting epidemiologic and mixed-methods studies, as well as surveillance and evaluation in partnership with public health agencies. She has published over 90 peer-reviewed publications and serves on the Editorial Board of the International Journal of Drug Policy. Dr. Park earned her Ph.D. and M.H.S. in Epidemiology at the Johns Hopkins University and B.S. from the University of Sydney.



Alexander Y. Walley, MD, MSc

Alexander Y. Walley is Professor of Medicine at Boston University Chobanian & Avedisian School of Medicine, primary care physician and addiction specialist at Boston Medical Center focused on the medical complications of substance use, specifically HIV and overdose. He leads research studies on overdose and the integration of addiction specialty care and general medical care. He is a founder of the inpatient addiction consult service and low barrier walk-in substance use care clinic at Boston Medical Center. Dr. Walley was a founding director of the Grayken Addiction Medicine Fellowship and is the president of the American College of Academic Addiction Medicine. He serves as the medical director for the Massachusetts Department of Public Health's Bureau of Substance Addiction Services and the Overdose Prevention Program.



Peter Davidson, PhD

Peter Davidson is a medical sociologist and associate professor in the Division of Infectious Disease & Global Public Health, UCSD Department of Medicine. Dr. Davidson has been conducting research and harm-reduction based intervention development in collaboration with community-based organizations serving people who use drugs and people engaged in commercial sex work in Australia and the United States since 1997. His recent research projects include a foundation-funded study of the impacts of a safe consumption site operating in the United States and a NIH/NIDA funded study of ethical issues which emerge when HIV researchers collaborate with community-based organizations serving marginalized populations. He is currently PI of an NIH/NIDA funded study of the impacts of a low threshold, high volume naloxone-on-release program in the Los Angeles County jail system.



Emmanuel Oga, MD

Emmanuel Oga is a distinguished senior research epidemiologist with a specialized focus on the epidemiological aspects of substance use, its connection to infectious diseases, and the efficacy of harm reduction approaches in treating opioid use disorder. He is dedicated to enhancing health outcomes in marginalized groups impacted by substance abuse, emphasizing community engagement, data-driven approaches and the creation of tailored interventions to mitigate substance use and its associated health consequences. At RTI International, Dr. Oga spearheads several key projects under the auspices of the National Institutes of Health's (NIH) Helping to End Addiction Long-term® Initiative. His leadership roles include directing the HEALing Communities Study Data Coordinating Center, the Harm Reduction Research Network Coordination Center, and the Stay Safe Study. Furthermore, Dr. Oga is deeply engaged in research exploring the effects of stigma on the health of vulnerable populations. His recent efforts include developing and validating tools to measure stigma among sex workers and drug users, a critical step forward in HIV/AIDS prevention and treatment strategies.



Hansel Tookes, MD, MPH

Hansel Tookes is Associate Professor of Medicine at The University of Miami. After completing his residency in Internal Medicine at Jackson Memorial Hospital, he founded IDEA Lab whose mission is to implement, disseminate, educate, and advocate for the health of people who use drugs. The IDEA Lab also houses the IDEA syringe services program – the first of its kind in Florida. Dr. Tookes spent five years lobbying the Florida Legislature for the creation of the program as an evidence-based HIV prevention intervention. In 2016, he succeeded, and the pilot was signed into law. Today, Dr. Tookes serves as medical director of IDEA and successfully passed Infectious Disease Elimination Act of 2019 authorizing statewide expansion of syringe services programs. As a physician at Jackson Memorial, one of the largest public hospitals in the nation, Dr. Tookes attends on the HIV service. He is an advocate for health equity and has extensive experience working with both patients of low socioeconomic status and individuals who use drugs. Dr. Tookes' research interests include structural and systemic interventions and innovative approaches to HIV prevention and treatment. He is a 2021 recipient of a \$2.5M NIDA Avenir Award which will test his innovative Tele-Harm Reduction model in a randomized controlled trial and, more recently, 2 NIDA R01s. He has received numerous honors, including Miami Chamber of Commerce Healthcare Hero, Starbucks Upstander, and SAVE Champion of Equality. In 2023, he was appointed to the board of the HIV Medical Association and the Presidential Advisory Council on HIV/AIDS.



Raagini Jawa, MD, MPH, FASAM

Raagini Jawa is an Assistant Professor and Clinician Investigator at the Center for Research on Health Care at the University of Pittsburgh. She is board certified in Internal Medicine, Infectious Disease, and Addiction Medicine and clinically works at University of Pittsburgh Medical Center providing treatment for substance use disorders and complex endovascular infections. She also is a wound care provider at Prevention Point Pittsburgh. She leads NIDA-funded research on the development and implementation of harm reduction services within traditional health settings for individuals who use substances. She has several research projects exploring ways to provide compassionate and evidenced-based care to persons who use drugs throughout the care continuum to mitigate drug-related harms including those from xylazine and other adulterants. She serves as a clinical harm reduction educator with Grayken Center for Addiction Training and Technical Assistance and is on the board of directors at Prevention Point Pittsburgh and Pennsylvania Harm Reduction Network.

Article II. Biosketches of Planning Committee Members

Alan Leshner, PhD (NAM)

Planning Committee Chair



Alan I. Leshner is the Chief Executive Officer, Emeritus of the American Association for the Advancement of Science (AAAS) and former Executive Publisher of the journal *Science*. Before joining AAAS, Dr. Leshner was Director of the National Institute on Drug Abuse at the National Institutes of Health. He also served as Deputy Director and Acting Director of the National Institute of Mental Health, and in several roles at the National Science Foundation. Previously, Dr. Leshner was Professor of Psychology at Bucknell University. Dr. Leshner is an elected fellow of AAAS, the American Academy of Arts and Sciences, and many others. He was a member and served as Vice Chair of the governing Council of the National Academy of Medicine (formerly the Institute of Medicine) of the National Academies of Sciences, Engineering and Medicine. He served two terms on the National Science Board, appointed first by President Bush and reappointed by President Obama. Dr. Leshner received M.S. and Ph.D. degrees in physiological psychology from Rutgers University and an A.B. in psychology from Franklin and Marshall College. Dr. Leshner has received many honors and awards, including the Walsh McDermott Medal from the National Academy of Medicine and seven honorary Doctor of Science degrees.



Magdalena Cerdá, DrPH

Magdalena Cerdá is a Professor and Director of the Center for Opioid Epidemiology and Policy, at the Department of Population Health at NYU Langone Health. Her work integrates approaches from social and psychiatric epidemiology to examine how social contexts and drug and health policies shape substance use and violent behavior. Current funded research focuses on the impact that state cannabis and overdose prevention policies, as well as local harm reduction policies and harm reduction programs, have on overdose and other drug-related harms. Her research also examines the use of machine learning and simulation models to forecast overdose hotspots and to estimate the potential impact of novel interventions to reduce overdose. She is a member of the National Academy of Medicine Action Collaborative on Combatting Substance Use and Opioid Crises, President of the Interdisciplinary Association of Population Health Sciences, and Senior Editor of the *International Journal of Drug Policy*. Dr. Cerdá obtained her doctorate from the Harvard University School of Public Health in 2006, and is a former Robert Wood Johnson Health and Society Scholar.



Chinazo Cunningham, MD, MS

Chinazo Cunningham is Commissioner of the New York State Office of Addiction Services and Supports, where she oversees one of the nation's largest system of substance use and addiction services. She is a physician, trained in internal medicine and addiction medicine, and has spent over 25 years providing care, developing programs, and conducting research with people who use drugs. For decades, she has collaborated with community-based harm reduction organizations and led one of the first programs in the US to integrate addiction treatment into primary care. Her work has focused on improving access to care, utilization of health care services, and health outcomes. Dr. Cunningham has authored over 150 peer-reviewed manuscripts and has been the principal investigator on numerous federally-funded grants. In addition to serving on and chairing several national advisory committees and guideline committees, she has trained hundreds of physicians and has been recognized by local and national awards.




Chin Hwa (Gina) Dahlem, PhD, MSN

Gina Dahlem is a Clinical Associate Professor at University of Michigan School of Nursing and a nurse practitioner at Packard Health serving people experiencing homelessness. Dr. Dahlem has been delivering overdose prevention education and implementing naloxone distribution programs for communities, first responders, and healthcare providers since 2013. Her expertise is in community-engaged research, implementing, and evaluating innovative harm reduction models of care to reduce the burden associated with opioid epidemic. She is a fellow of American Association of Nurse Practitioners, co-inventor of an adolescent risk assessment screening tool, RAAPS, and the recipient of 2023 UMSN Alumni Award for Excellence in Nursing Research and Scholarship.




Helena Hansen, MD, PhD (NAM)

Helena Hansen is a psychiatrist-anthropologist, Professor, and Interim Chair of Psychiatry and Biobehavioral Sciences at UCLA's David Geffen School of Medicine and Interim Director of the Semel Institute for Neuroscience and Human Behavior. She is the author of over 100 articles in leading clinical and social science journals, and of three books: *Addicted to Christ: Remaking Men in Puerto Rican Pentecostal Drug Ministries*; *Structural Competency in Medicine and Mental Health: A Case-Based Approach to Treating the Social Determinants of Health* (with Jonathan Metzl); and *Whiteout: How Racial Capitalism Changed the Color of Heroin in America* (with Jules Netherland and David Herzberg). She has received numerous awards, including an honorary doctorate from Mount Sinai School of Medicine in New York, and election to the National Academy of Medicine.



Jeffrey Hom, MD, MSPH, MPH

Jeffrey Hom is the director of Population Behavioral Health in the San Francisco Department of Public Health, which uses population-level and equity-driven approaches to advance the wellbeing of San Franciscans. A board-certified internist, Jeff oversees the department's Office of Overdose Prevention, focusing on reducing overdoses and the harms associated with substance use. Jeff most recently served as the medical director of the Division of Substance Use Prevention and Harm Reduction in the Philadelphia Department of Public Health, where he helped lead the City's response to addiction and overdose. He was also a faculty member at the University of Pennsylvania and the Jefferson College of Population Health, where he taught graduate courses on substance use as a public health issue. For his efforts Jeff has been a Zuckerman Fellow at Harvard's Center for Public Leadership, a Fellow of the College of Physicians of Philadelphia, a TEDx speaker, and awarded the Common Good Award by Bowdoin College's Board of Trustees. Jeff received his MD from Harvard Medical School and his MPH from the Harvard School of Public Health. He completed his internal medicine residency at UCSF and fellowship as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, where he obtained his Master of Science in Health Policy Research. He is currently pursuing a Doctor of Public Health as a Bloomberg Fellow at the Johns Hopkins Bloomberg School of Public Health.



Kevin L. Larsen, MD

Kevin Larsen is the Senior Vice President of Clinical Innovation at Optum. Kevin's role is to provide clinical leadership and a clinical voice to Optum Center for Advanced Clinical Solutions. He leads the clinical and informatics team in building and deploying provider enablement technologies, including clinical decision support integrated through electronic health records. Previously he was the Chief Medical Officer of OptumLabs where he supported the design and implementation of innovative research, analytics and evidence-based translation programs in diverse areas across our portfolio. Additionally, he was the primary clinical lead of the Optum Enterprise strategy, an initiative to modernize and integrate Optum products and services. Kevin is an internist and medical informaticist who started his career at Hennepin County Medical Center in Minneapolis where he had a variety of executive and clinical leadership roles. He has worked in academic, hospital and government settings, focusing on innovation through data and analytics, research, policy and developing/implementing novel programs at scale. He joined Optum from the US Department of Health and Human Services (HHS), where most recently he has been Senior Health IT Advisor at the office of the Chief Technology Officer. There he was the executive lead for the 10-billion-dollar Indian Health Service Electronic Health Record Modernization Project. Kevin established and led the Centers for Medicare and Medicaid Services (CMS) strategic planning and transformation team under Dr. Patrick Conway and Andy Slavitt.



Stephan Murray, MPH, NRP

Stephen Murray is an overdose researcher, Harm Reduction Program Manager and the Director of the Massachusetts Overdose Prevention Helpline at Boston Medical Center. In 2021, he retired as a Lieutenant at a large regional ambulance service in Western Massachusetts, and had served as a first responder since 2013, having worked both as a firefighter and paramedic. He regularly shares for a national audience about his lived experience as a person who used drugs and overdose survivor. Stephen provides expert technical assistance around the topics of overdose prevention, emergency medical services and harm reduction to a variety of organizations, county and state governments across the country, including the Commonwealth of Massachusetts, Substance Abuse and Mental Health Services Agency and the National Governors Association. He has guest lectured at Harvard University, Northeastern University, UMASS Medical School, University of Pittsburgh, Boston University, Temple University and Ohio State University, and has had research published in the International Journal of Drug Policy, American Journal of Public Health and Health Promotion Practice. In September 2023, he was featured in Episode 809 ("The Call") on This American Life.




Nabarun Dasgupta, PhD, MPH

Nabarun Dasgupta is a scientist-activist at the University of North Carolina with two decades of experience in harm reduction, focused on overdose epidemiology and prevention. His passion is telling true stories about health, with numbers. His multidisciplinary approach draws on large database analytics, qualitative field studies, chemistry laboratory drug checking, randomized message trials, and community-based interventions. He is an Associate Editor at the American Journal of Public Health, focusing on substance use and methods-related submissions. At UNC he works at the Opioid Data Lab, a multi-university team of scientists exploring difficult epidemiology methods questions in overdose. He is a co-founder of Remedy Alliance For The People (remedyallianceftp.org), a groundbreaking non-profit that distributes free and at-cost bulk naloxone. He also co-founded the UNC Street Drug Analysis Lab (<https://streetsafe.supply>), which provides mail-in drug checking services to 160+ programs in 35+ states. In 2023 Dr. Dasgupta was named to TIME 100 Next list of emerging global leaders: "Few Americans have done more to prevent drug-overdose deaths than Nabarun Dasgupta."



Corey Davis, JD, MSPH

Corey Davis serves as the Director of the Network for Public Health Law's Harm Reduction Legal Project. Corey was previously a Senior Attorney at the National Health Law Program (NHeLP), where he helped to advance access to quality health care for low-income and underserved individuals. Before joining NHeLP Corey served as Employment Rights Attorney at Equality Advocates Pennsylvania, where he represented lesbian, gay, bisexual and transgender (LGBT) individuals before administrative commissions and in state and federal courts. He previously oversaw a street-based legal clinic sited at Philadelphia's syringe exchange program. Corey has served as chair of a county board of health, chair of the board of the North Carolina Harm Reduction Coalition, and vice-chair of the North Carolina Harm Public Health Foundation, among other positions. He is a recipient of the International AIDS Society's Young Investigator Award and has published extensively in the lay and academic press. Corey received his B.S. from the Indiana University of Pennsylvania, his M.S.P.H. from the University of North Carolina at Chapel Hill and his J.D. from Temple University. Corey is barred in Pennsylvania and New Jersey as well as various federal courts.



Ruchi Fitzgerald, MD, FAAFP

Ruchi Fitzgerald is an Assistant Professor in the Departments of Family Medicine and Psychiatry/Behavioral Sciences at Rush University. She is also the Associate Program Director of the Rush University Addiction Medicine Fellowship. She is the Service Chief of Inpatient Addiction Medicine at PCC Community Wellness Center, a federally qualified health center system that serves the West Side of Chicago. Dr. Fitzgerald is a National Academy of Medicine James C. Puffer/American Board of Family Medicine fellow. Dr. Fitzgerald's work has focused on promoting cross-sector collaboration to improve care for persons affected by substance use disorders, with an emphasis in the perinatal/child health arena. Her scholarly work has focused on addressing stigma, building capacity in primary care for treating opioid use disorder in special populations, and implementing evidence-based substance use disorder curricula in the next generation of clinicians. Dr. Fitzgerald received her MD from the University of Michigan Medical School and completed her Family Medicine training with the Montana Family Medicine Residency and her Addiction Medicine fellowship with Rush University.

Tracie Gardner, BA



Tracie Gardner is the Legal Action Center's Senior Vice President of Policy Advocacy. Ms. Gardner oversees LAC's New York, Federal and state-based policy advocacy work on the Center's core issues related to substance use, harm reduction and criminal legal system reform. Ms. Gardner has worked more than 30 years in the health and social services policy arena as a policy advocate, trainer and lobbyist. From 2015-2017, Ms. Gardner served as the Assistant Secretary of Mental Hygiene for New York State, where she oversaw the state's addiction, mental health and developmental disabilities agencies. Ms. Gardner is a nationally recognized expert on health and communities of color especially in the area of substance use and the impact of the War on Drugs and incarceration on Black communities in this country. She is a highly requested speaker on these issues and has been extensively quoted in the media and has contributed to various research and journal articles on institutional racism's impact on the health and criminal legal system. She is the primary author of LAC's 2018 report: Health and Justice: Bridging the Gap, which details New York's efforts to enroll incarcerated individuals in Medicaid and connect them to community-based care upon release and helped author LAC's 2022 Blueprint for Transforming Criminal Legal System Outcomes in NYC.



Glyceria (Ria) Tsinas

Ria Tsinas was the co-chair of the National Perinatal Association's family toolkit workgroup from 2016 to 2018, and co-chair of the 2018 conference planning committee. Ria volunteered in direct service syringe access for the People's Harm Reduction Alliance from 2010 to 2015 and served on the Board of Directors from 2017 to 2019. She has worked in both the public and private sectors of syringe access, most notably as an education specialist for King County Public Health in Seattle, WA. Ria also served as a residential counselor at Downtown Emergency Service Center, as well as the YWCA Angeline's drop-in and winter response shelter in Seattle. Ria's work has been highlighted in publications such as Undark, Filter, and the Daily (University of Washington student newsletter). She is a peer reviewer for the American Journal of Public Health. A long, long time ago, she was a southwestern archaeologist. Ria works tirelessly to push back on antiquated narratives about drug use and parenting. Her dynamic and unique blend of equal parts harm reduction professional and drug war survivor position her to create grounded yet innovative solutions to complex problems. Ria spends most of her days working at a non-profit syringe exchange program in Portland, OR. When not working, she chases around her daughter, Lola. Together, they love going on outdoor adventures, musicals, cracking sarcastic jokes, and talking about the coolest thing there is to be on earth – Kind.

Article III. Preventing Discrimination, Harassment, and Bullying Expectations for Participants in NASEM Activities

The National Academies of Sciences, Engineering, and Medicine (NASEM) are committed to the principles of diversity, integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. All forms of discrimination, harassment, and bullying are prohibited in any NASEM activity. This commitment applies to all participants in all settings and locations in which NASEM work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Discrimination is prejudicial treatment of individuals or groups of people based on their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.

Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.

Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Section 3.01 REPORTING AND RESOLUTION

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint with the Office of Human Resources at 202-334-3400, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.

If an investigation results in a finding that an individual has committed a violation, NASEM will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances the removal of an individual from current NASEM activities and a ban on participation in future activities.

Section 3.02 CONFIDENTIALITY

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. NASEM will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Article IV. Diversity, Equity, and Inclusion Statement and Guiding Principles

We, the National Academies of Sciences, Engineering, and Medicine (the National Academies), value diversity among our staff, members, volunteers, partners, vendors, and audiences. We recognize that talent is broadly distributed in society and that many perspectives enhance the quality of our work and drive innovation and impact.

We pledge to cultivate a workplace culture and climate that promotes inclusion, belonging, accessibility, and anti-racism; upholds equity; and values the participation of all who are engaged in advancing our mission.^[1] By embracing the values of diversity, equity, and inclusion in our programs, institutional policies and practices, and products, we will be able to better advise the nation on the most complex issues facing society and the world.

Guiding Principles:

The following diversity, equity, and inclusion principles guide our work at the National Academies:

1. Integrate diverse perspectives and experiences into our programs, institutional policies and practices, and products.
2. Foster a culture of inclusion where all staff, members, and volunteers have full access to participation and feel welcomed, respected, valued, and a sense of belonging.
3. Approach scientific endeavors with a consideration of diversity, equity, and inclusion frameworks.
4. Cultivate mutually beneficial diverse partnerships and collaborations with a variety of communities, including, but not limited to, marginalized and underrepresented communities.

Our institutional strategy for putting these values and principles into practice are outlined in the National Academies DEI Action Plan, a comprehensive five-year plan that charts a path toward achieving our diversity, equity, and inclusion goals. The DEI Action Plan is one of many ways that we commit to systems of accountability and transparency to uphold these principles and allow for continuous learning and improvement.

^[1] The National Academies' mission is to provide independent, trustworthy advice and facilitate solutions to complex challenges by mobilizing expertise, practice, and knowledge in science, engineering, and medicine.

Updated June 7, 2018